Bruker Corporation (NASDAQ:BRKR) reported third-quarter 2025 earnings that topped expectations, but its shares fell 3.2% in premarket trading after the company issued a full-year forecast that disappointed investors.
The scientific instruments manufacturer posted adjusted earnings of $0.45 per share, surpassing the analyst consensus of $0.33. Revenue came in at $860.5 million, ahead of expectations of $847 million, though this marked a 0.5% year-over-year decline and a 4.5% drop organically.
The stock fell after Bruker trimmed its 2025 full-year guidance, now projecting adjusted EPS between $1.85 and $1.90, slightly below the $1.94 consensus estimate. The company also expects annual revenue of $3.41 billion to $3.44 billion, landing at the lower end of analysts’ forecasts.
“In the third quarter, we were encouraged by our mid-single digit percentage organic bookings growth year-over-year, with a Scientific Instruments segment book-to-bill ratio greater than 1.0,” said Frank H. Laukien, Bruker’s President and CEO. “For the first time this year, we saw strength in bookings in the academic/government market segment, as well as improving biopharma and applied markets orders.”
The company posted a GAAP operating loss of $51.8 million, compared to operating income of $68.1 million in the same quarter last year. Results were impacted by non-cash impairment charges of $119.4 million tied to goodwill and intangible assets, as well as restructuring costs of $34.5 million.
Despite near-term headwinds, Bruker said its cost reduction initiatives are progressing ahead of plan, targeting the upper range of $100–$120 million in savings, and are expected to drive significant operating margin expansion and EPS growth in 2026.